|
1
|
Waks AG and Winer EP: Breast cancer
treatment: A review. Jama. 321:288–300. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Murphy CG and Dickler MN: Endocrine
resistance in hormone-responsive breast cancer: Mechanisms and
therapeutic strategies. Endocr Relat Cancer. 23:R337–R352. 2016.
View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Ziauddin MF, Hua D and Tang SC: Emerging
strategies to overcome resistance to endocrine therapy for breast
cancer. Cancer Metastasis Rev. 33:791–807. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Mills JN, Rutkovsky AC and Giordano A:
Mechanisms of resistance in estrogen receptor positive breast
cancer: Overcoming resistance to tamoxifen/aromatase inhibitors.
Curr Opin Pharmacol. 41:59–65. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Won HS, Lee KM, Oh JE, Nam EM and Lee KE:
Inhibition of β-catenin to overcome endocrine resistance in
tamoxifen-resistant breast cancer cell line. PLoS One.
11:e01559832016. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Clarke R, Tyson JJ and Dixon JM: Endocrine
resistance in breast cancer-An overview and update. Mol Cell
Endocrinol. 418Pt:220–234. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Beaver JA and Park BH: The BOLERO-2 trial:
The addition of everolimus to exemestane in the treatment of
postmenopausal hormone receptor-positive advanced breast cancer.
Future Oncol. 8:651–657. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Bachelot T, Bourgier C, Cropet C,
Ray-Coquard I, Ferrero JM, Freyer G, Abadie-Lacourtoisie S, Eymard
JC, Debled M, Spaëth D, et al: Randomized phase II trial of
everolimus in combination with tamoxifen in patients with hormone
receptor-positive, human epidermal growth factor receptor
2-negative metastatic breast cancer with prior exposure to
aromatase inhibitors: A GINECO study. J Clin Oncol. 30:2718–2724.
2012. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Rodriguez D, Ramkairsingh M, Lin X, Kapoor
A, Major P and Tang D: The central contributions of breast cancer
stem cells in developing resistance to endocrine therapy in
estrogen receptor (ER)-positive breast cancer. Cancers (Basel).
11:10282019. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Liu H, Zhang HW, Sun XF, Guo XH, He YN,
Cui SD and Fan QX: Tamoxifen-resistant breast cancer cells possess
cancer stem-like cell properties. Chin Med J (Engl). 126:3030–3034.
2013.PubMed/NCBI
|
|
11
|
Sakunrangsit N and Ketchart W: Plumbagin
inhibits cancer stem-like cells, angiogenesis and suppresses cell
proliferation and invasion by targeting Wnt/β-catenin pathway in
endocrine resistant breast cancer. Pharmacol Res. 150:1045172019.
View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Yin S, Cheryan VT, Xu L, Rishi AK and
Reddy KB: Myc mediates cancer stem-like cells and EMT changes in
triple negative breast cancers cells. PLoS One. 12:e01835782017.
View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Mukherjee N and Panda CK: Wnt/β-catenin
signaling pathway as chemotherapeutic target in breast cancer: An
update on pros and cons. Clin Breast Cancer. 20:361–370. 2020.
View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Marotta LL, Almendro V, Marusyk A,
Shipitsin M, Schemme J, Walker SR, Bloushtain-Qimron N, Kim JJ,
Choudhury SA, Maruyama R, et al: The JAK2/STAT3 signaling pathway
is required for growth of CD44+CD24− stem
cell-like breast cancer cells in human tumors. J Clin Invest.
121:2723–2735. 2011. View
Article : Google Scholar : PubMed/NCBI
|
|
15
|
Shang S, Hua F and Hu ZW: The regulation
of β-catenin activity and function in cancer: Therapeutic
opportunities. Oncotarget. 8:33972–33989. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Damsky WE, Curley DP, Santhanakrishnan M,
Rosenbaum LE, Platt JT, Rothberg BE, Taketo MM, Dankort D, Rimm DL,
McMahon M and Bosenberg M: β-catenin signaling controls metastasis
in Braf-activated Pten-deficient melanomas. Cancer Cell.
20:741–754. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Vilchez V, Turcios L, Marti F and Gedaly
R: Targeting Wnt/β-catenin pathway in hepatocellular carcinoma
treatment. World J Gastroenterol. 22:823–832. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Liu F, Xia Z, Zhang M, Ding J, Feng Y, Wu
J, Dong Y, Gao W, Han Z, Liu Y, et al: SMARCAD1 promotes pancreatic
cancer cell growth and metastasis through Wnt/β-catenin-mediated
EMT. Int J Biol Sci. 15:636–646. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Liu Y, Chen H, Zheng P, Zheng Y, Luo Q,
Xie G, Ma Y and Shen L: ICG-001 suppresses growth of gastric cancer
cells and reduces chemoresistance of cancer stem cell-like
population. J Exp Clin Cancer Res. 36:1252017. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Yin P, Wang W, Zhang Z, Bai Y, Gao J and
Zhao C: Wnt signaling in human and mouse breast cancer: Focusing on
wnt ligands, receptors and antagonists. Cancer Sci. 109:3368–3375.
2018. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Khramtsov AI, Khramtsova GF, Tretiakova M,
Huo D, Olopade OI and Goss KH: Wnt/beta-catenin pathway activation
is enriched in basal-like breast cancers and predicts poor outcome.
Am J Pathol. 176:2911–2920. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Bilir B, Kucuk O and Moreno CS: Wnt
signaling blockage inhibits cell proliferation and migration, and
induces apoptosis in triple-negative breast cancer cells. J Transl
Med. 11:2802013. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Lv C, Li F, Li X, Tian Y, Zhang Y, Sheng
X, Song Y, Meng Q, Yuan S, Luan L, et al: MiR-31 promotes mammary
stem cell expansion and breast tumorigenesis by suppressing Wnt
signaling antagonists. Nat Commun. 8:10362017. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Katoh M: Multi-layered prevention and
treatment of chronic inflammation, organ fibrosis and cancer
associated with canonical WNT/β-catenin signaling activation
(Review). Int J Mol Med. 42:713–725. 2018.PubMed/NCBI
|
|
25
|
Arensman MD, Telesca D, Lay AR, Kershaw
KM, Wu N, Donahue TR and Dawson DW: The CREB-binding protein
inhibitor ICG-001 suppresses pancreatic cancer growth. Mol Cancer
Ther. 13:2303–2314. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Kartha VK, Alamoud KA, Sadykov K, Nguyen
BC, Laroche F, Feng H, Lee J, Pai SI, Varelas X, Egloff AM, et al:
Functional and genomic analyses reveal therapeutic potential of
targeting β-catenin/CBP activity in head and neck cancer. Genome
Med. 10:542018. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Turner NC, Ro J, André F, Loi S, Verma S,
Iwata H, Harbeck N, Loibl S, Bartlett CH, Zhang K, et al:
Palbociclib in hormone-receptor-positive advanced breast cancer. N
Engl J Med. 373:209–219. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Sledge GW Jr, Toi M, Neven P, Sohn J,
Inoue K, Pivot X, Burdaeva O, Okera M, Masuda N, Kaufman PA, et al:
MONARCH 2: Abemaciclib in combination with fulvestrant in women
with HR+/HER2-advanced breast cancer who had progressed while
receiving endocrine therapy. J Clin Oncol. 35:2875–2884. 2017.
View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Slamon DJ, Neven P, Chia S, Fasching PA,
De Laurentiis M, Im SA, Petrakova K, Bianchi GV, Esteva FJ, Martín
M, et al: Phase III randomized study of ribociclib and fulvestrant
in hormone receptor-positive, human epidermal growth factor
receptor 2-negative advanced breast cancer: MONALEESA-3. J Clin
Oncol. 36:2465–2472. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Clevers H: Wnt/beta-catenin signaling in
development and disease. Cell. 127:469–480. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Bijnsdorp IV, Giovannetti E and Peters GJ:
Analysis of drug interactions. Methods Mol Biol. 731:421–434. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Finn RS, Martin M, Rugo HS, Jones S, Im
SA, Gelmon K, Harbeck N, Lipatov ON, Walshe JM, Moulder S, et al:
Palbociclib and letrozole in advanced breast cancer. N Engl J Med.
375:1925–1936. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Kim JW, Gautam J, Kim JE, Kim JA and Kang
KW: Inhibition of tumor growth and angiogenesis of
tamoxifen-resistant breast cancer cells by ruxolitinib, a selective
JAK2 inhibitor. Oncol Lett. 17:3981–3989. 2019.PubMed/NCBI
|
|
34
|
Yan S, Zhou C, Zhang W, Zhang G, Zhao X,
Yang S, Wang Y, Lu N, Zhu H and Xu N: beta-catenin/TCF pathway
upregulates STAT3 expression in human esophageal squamous cell
carcinoma. Cancer Lett. 271:85–97. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Armanious H, Gelebart P, Mackey J, Ma Y
and Lai R: STAT3 upregulates the protein expression and
transcriptional activity of β-catenin in breast cancer. Int J Clin
Exp Pathol. 3:654–664. 2010.PubMed/NCBI
|
|
36
|
Huang R, Wang S, Wang N, Zheng Y, Zhou J,
Yang B, Wang X, Zhang J, Guo L, Wang S, et al: CCL5 derived from
tumor-associated macrophages promotes prostate cancer stem cells
and metastasis via activating β-catenin/STAT3 signaling. Cell Death
Dis. 11:2342020. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Kawasaki K, Kuboki S, Furukawa K,
Takayashiki T, Takano S and Ohtsuka M: LGR5 induces β-catenin
activation and augments tumour progression by activating STAT3 in
human intrahepatic cholangiocarcinoma. Liver Int. 41:865–881. 2021.
View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Kettner NM, Vijayaraghavan S, Durak MG,
Bui T, Kohansal M, Ha MJ, Liu B, Rao X, Wang J, Yi M, et al:
Combined inhibition of STAT3 and DNA repair in
palbociclib-resistant ER-positive breast cancer. Clin Cancer Res.
25:3996–4013. 2019. View Article : Google Scholar : PubMed/NCBI
|
